Clinitalk vs SCA Prep: Consultation Feedback vs AI Case Generation

Featured image for Clinitalk vs SCA Prep: Consultation Feedback vs AI Case Generation

Clinitalk and SCA Prep are not competing — they are complementary tools that address different stages of the preparation cycle.

Clinitalk is retrospective. You record a consultation (real or role-played), and the AI analyses your performance against SCA marking criteria. The output is structured feedback on your consulting behaviour — what you did well, what cost you marks, and where your guideline adherence could improve. Created by RCGP examiners, the feedback reflects genuine examiner expectations. It includes a trainer dashboard for educational supervisors to track your progress.

SCA Prep is prospective. You generate unlimited new cases across all 12 RCGP clinical experience groups, practise them with AI patient roleplays, and receive RCGP-criteria marking. The AI tutor provides guideline-based answers to clinical questions. The WhatsApp bot delivers daily revision prompts. From £14.95/month.

When to Use Each

Clinitalk works throughout training — you can record consultations from ST1 to ST3 and track your consulting development longitudinally. The value increases with consistent use, as patterns in your consulting become visible over weeks and months.

SCA Prep works best in dedicated revision blocks — the unlimited case generator is most useful when you are actively preparing for a specific SCA diet and want high-volume case exposure across all domains.

Clinitalk needs input (your recording). SCA Prep generates output (new cases). If you have no recordings and no partner, Clinitalk cannot help. If you have recordings but want feedback rather than new cases, SCA Prep is less relevant.

Where iatroX Fits

Clinitalk shows you how you consult. SCA Prep gives you what to consult about. iatroX ensures you know the clinical content to consult correctly — adaptive knowledge revision and guideline Q&A that underpins both consultation analysis and case practice.

Share this insight